Abstract Cancer stem cells (CSC) are resistant to chemoand radiotherapy. To eliminate cells with phenotypic markers of CSC-like we characterized: (1) expression of CD44, CD24, CD133 and MIC-A/B (NKG2 receptors) in breast (MCF7) and ovarian (SK-OV-3) cells resistant to gemcitabine (GEM), paclitaxel (PTX) and 5-Xuorouracil (5-FU) and (2) 
.
Breast cancer cells with high levels of CD44 (CD44 hi ) and absent or low CD24 (CD24 neg/lo ) expression have functional characteristics of CSC. Brain, colon and prostate cancer cells with CSC-characteristics express CD133 (prominin-1) [1, 3, 10, 28, 31] .
The levels of CD44 (an adhesion molecule which binds to hyaluronate) directly correlate with metastasis in breast cancer. The levels of CD24 (an adhesion molecule that binds P-selectin) inversely correlate with survival of ovarian cancer patients. Studies in human mammary cells suggest that the most primitive mammary cells do not express estrogen-receptors, but are capable to diVerentiate to estrogen positive, luminal epithelial cells [6, 18, 24, 33] .
CSC are more resistant to chemo-and radiotherapy than non-CSC [17, 25] . Histone-deacetylase (HDAC) and poly-A-ribose polymerase (PARP)-inhibitors are weak anti-CSC eVectors. To avoid toxicity, it was proposed to lower doses of standard chemotherapy when used together with HDAC/ PARP inhibitors [12, 26, 27] .
A novel approach to cancer therapy is to eliminate CSC with immune eVectors. We hypothesized that we can eliminate CSC by targeting peptides from the antagonistic Notch and Numb proteins with cytotoxic T lymphocytes (CTL). When CSC renew or become quiescent Notch and Numb induce degradation of each other, respectively. Notch and Numb are degraded to peptides by the proteasome. Peptides from NICD and Numb proteins are presented by HLA-class I molecules of cancer cells to T cells.
Hetero-dimeric Notch (hNotch) consists of an extracellular domain named NECD and a trans-membrane and intracellular domain, named NICD. NICD and NECD are linked by disulWde bonds. hNotch, located trans-membrane, is activated by its ligands. Human Notch-ligands belong to the Jagged (Jag) and Delta-like (DLL) families. Activation/ inhibition of Notch can proceed in Cis-by Notch ligands expressed on the responding cell or in Trans-from Notchligand expressed by neighboring cells. Notch signals are transduced i by NICD, which activates gene transcription [14] .
Numb has four isoforms. They form two groups Numb-Long (Numb-L) and Numb-Short (Numb-S) which diVer in length by 5 kDa. Each group has two isoforms, which diVer by 1 kDa, and are diYcult to distinguish. Both Numb-L and Numb-S are present in cancer cells. However, most human cancer studies do not resolve Numb-S from Numb-L and Numb-like [19] . Non-phosphorylated Numb is adjacent to membrane. [4, 32] .
Symmetric division of stem cells which lack Numb, double the number of "mother" stem cells. Asymmetric division of cells which contain both Notch and Numb results in one "mother" stem cell and one diVerent cell [daughter/IPstem cell [4, 32] ]. Degradation of NICD by Numb inhibits activation of transcription by NICD and cells become quiescent [9, 11, 19] .
The aim of this study was to determine whether: (1) the proportion of cells with CSC-phenotype/putative CSC increases in drug-resistant cancer lines, and (2) drug-resistant cells with CSC-phenotype can be eliminated by Notchand Numb-peptide activated CTL.
We 
Materials and methods

Cell lines and drugs
MCF7 and SK-OV-3 cell lines were from ATCC (Manassas, VA). Cells were cultured in RPMI 1640 medium with 10% FBS, 100 U/L penicillin, and 100 g/mL streptomycin. We used gemcitabine (Eli-Lilly Indianapolis, IN), paclitaxel (Bristol-Myers Squibb, Princeton, NJ), 5 The 50% inhibitory concentration (IC 50 ) of GEM, PTX and 5-FU was determined after a 72-h incubation with drugs as described [13] . ) were cultured with drugs at 2 £ IC 50 for 4 days followed by drug at 0.5-1.0 £ IC 50 for the next 3-6 days. Surviving cells (2 £ 10 5 ) were incubated Wrst with 20 g of human IgG (Sigma) for 1 h on ice to inhibit nonspeciWc binding of speciWc mAb during staining. Analysis was performed using a Becton Dickinson FACS Calibur with Cell Quest software (BD). Expression of CD24, CD44 and CD133 was quantiWed in gated ESA + cells as described [16] . 
Activation of GEM
Res MCF7 cells
Cells were stimulated for 24 h in serum free medium with 62.5 ng/mL rhDLL4 then cultured with or without GEM for 7 days. GEM Res MCF7 cells were stimulated three times with DLL4 (62.5 ng/mL) weakly for 24 h.
Sensitivity of GEM
Res MCF7 cells to HLA-A2 + PBMC activated by Notch-and Numb-peptides Notch-1 = NICD peptide (2,112-2,120) and Numb-1 = Numb-1-PTB domain peptide (87-95) were previously identiWed by us as immunogenic [15] . Non-adherent PBMC were activated with peptide-pulsed autologous immature monocyte-derived dendritic cells (iDC), or T2 cells as we described [37] . In all activation procedures, we used IL-12 as co-factor followed by IL-2 48 h later.
Immunoselection
Because autologous T cells to MCF-7 are not available, we used allogeneic immunoselection. GEM Res MCF7 cells (1.0 £ 10 5 ) were co-cultured in six-well plates with 3.0 £ 10 5 IL-2-activated, Notch-1-, or Numb-1-peptideactivated PBMC for 5 days. IL-2 was not added to cultures for 72 h before use. Residual IL-2 was washed out. Surviving MCF7 cells were analyzed by Xow-cytometry.
Western blot
Cell lysates with nuclei removed were prepared from live MCF7, and SK-OV-3 cells. Immunoblotting and quantiWcation of NECD, NICD, Numb, and Bcl-2 utilizing -actin as a reference was performed in relation to actin in the same sample, as we described [8, 37] .
Results
The higher. This means that less of Notch-1-ER-precursor was cleaved to TMIC (Fig. 3a) . The levels of TMIC were lower than in control cells. The levels of Numb were slightly lower in GEM Res and untreated MCF7 cells (Fig. 3a) . The ratio of NECD and TMIC (pre-NICD) to Numb-L and Numb-S decreased (see OD values). Therefore "quiescent" GEM Res MCF7 cells have lower levels of Notch-NECD than "quiescent" GEM Sens MCF7 cells. Control, dividing SK-OV-3 cells synthesized high amounts of Notch and expressed both TMIC (of 100 kDa) and NICD (of 80 kDa) (Fig. 3c) .
Numb-L and Numb-S were [P]-lated at Ser (Fig. 3c) . (Fig. 4a, b) . The Numb-1 peptide was more immunogenic than the Notch-1 peptide because it activated more CD8 + cells at 1 M, whereas Notch-1 did so at a concentration of 5 M.
Numb-1 peptide-activated PBMC produced IFNwhen incubated with SK-OV-3.A2 cells Numb-1 and NICD-1 peptide-activated PBMC produced similar amounts of IFN-, in the Wrst 24 h of co-culture with SK-OV-3.A2 cells. The same levels of IFN-were produced by control peptide, Notch-1-1947, which is not generated by proteasome. The SK-OV-3.A2 cell line acquires expression of HLA-A2 following transfection with a HLA-A2 expression plasmid. IFN-produced by Numb-1-activated cells doubled at 48 h of co-culture. The amount of IFN-produced by Notch-1-activated cells did not increase and remained similar to the amount produced by IL-2 activated cells (Fig. 4c) . Therefore, either SK-OV-3 cells presented more Numb-1 peptide than Notch-1 peptide to CD8 + cells, or Numb-1-CD8 + cells have higher functional avidity for HLA-A2-Numb-1 peptide complexes.
To identify whether Numb-degradation is activated by [P]-lation, we repeated the experiment with inhibitors of Ser-Thr-kinases Wortmanin did not inhibit presentation of the Numb-1 peptide, while SB-20380 had a marginal late eVect (Fig. 4d) . The strongest inhibition of Numb-1 peptide presentation was mediated by staurosporine, a broad-spectrum inhibitor of protein-serine-threonine kinase family, indicating that an identiWed kinase is involved in Numb [P]-lation and degradation. (Fig. 5b) . Notch-1-positive cells decreased by 68.5% (from 45.4 to 14.3%) after co-culture with Notch-1 peptide-activated PBMC (Fig. 5d) . Numb-1 peptide-activated PBMC decreased the NICD + cells only by 25.3% (from 45.4 to 33.9%), whereas IL-2-activated non-speciWc PBMC had no signiWcant eVect (Fig. 5c, e) . Therefore, Notch-1-speciWc CD8 + T cells speciWcally eliminated NICD + cells.
GEM
To eliminate cells with CSC markers we repeated the experiments and quantiWed each surviving population of CD44 CD24 cells. To increase stringency of elimination, we used as target MCF7 cells because they expressed less Numb-L and ten times less Numb-S than SK-OV-3 cells.
Numb-1-activated T cells were more eVective than Notch-1 and IL-2-activated eVectors. Only 10% of the initially plated GEM Res cells survived. The majority of surviving cells were CD44 hi CD24 lo . Numb-1-activated cells eliminated 2-3 times more CD44 hi CD24 lo MCF7 cells than other eVectors (Fig. 5f . Columns All and CD44 hi CD24 lo ). Per eVecter-cell number, Numb-1-peptide activated cells were more eVective than IL-2-activated cells, in eliminating CD44 hi CD24 hi cells (Fig. 5f , Column CD44 hi CD24 hi ).
Discussion
We identiWed populations in breast and ovarian tumor cell lines which express the phenotypes of breast (ESA + / CD44 + /CD24 GEM and 5-FU are inhibitors of DNA and RNA synthesis, which are incorporated in newly synthesized strands. Neither GEM nor 5-FU aVects cells in G 1 phase [36] . These We found only small diVerences in proliferation of CD24 ¡ and CD24 + cells when stimulated with medium, and found diVerences when cells were stimulated with DLL4. Cell-cycle analysis indicates that most cells were in G1 phase and only a small fraction less than 5% were in G2 M phase (Supplemental Figure 1) . We used stringent conditions for isolation of these cells by maintaining the drug in culture for several weeks. All non-adherent cells died in these conditions. In clinical practice, the drug given to patient starts decaying and only a small amount is present several days later. When MCF7 cells were cultured in Fig. 5 [35] .
[P]-Numb does not bind integrins when [P]-lated by atypical protein kinase-C (aPKC). Numb-[P]-Ser 295 recruits 14-3-3 proteins, which inhibit the binding with AP-2 complex in vitro [22] . Although the 14-3-3-vector rescued Numb-S from degradation in normal MCF-10A cells, Numb-S was not protected by 14-3-3-from degradation in MCF7 cells (Fig. 6) .
In normal cells, the Polo-kinase-1, Plk-1 regulates Numb asymmetry by [P]-lation of Pon [38] . The use of Polo-and Aurora-kinase inhibitors, in cancer treatment, raises the question whether more CSC will remain temporarily quiescent, or they will activate Notch when Numb decays and accelerate cancer progression. If this is the case, Numb-1 CTL can eliminate Plk-1-inhibitor-surviving cells. When this paper was prepared for publication two independent studies estimated the number of cells with CSC-characteristics in MCF7 to 2.4%. MCF7 cells formed mammospheres and required IL-6 to upregulate Notch-3 [7, 29] .
In conclusion, we found that Numb-1 speciWc CTL can eliminate CD44
hi CD24 neg/lo cells. Based on our Wndings, adoptive and active immunotherapy (vaccines) with Notch and Numb should be eVective in eliminating "quiescent CSC" in patients with breast and ovarian cancer. 
